Pharmaceutical Technology's Manufacturers' Rankings - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Manufacturers' Rankings
Pharmaceutical Technology&s Annual Manufacturers' Rankings provides perspectives on revenues, product positioning, R&D spending, pharmaceutical manufacturing activity, and capital projects of the major drug companies.

Pharmaceutical Technology

Manufacturing activity in Big Pharma

Pfizer. Pfizer announced plans earlier this year to reduce its workforce by 10%, exit five manufacturing facilities, rationalize R&D operations, and restructure its US pharmaceutical operations. The announcement comes as the company expects its 2007 and 2008 revenues to be comparable to 2006 levels.

Since the Pharmacia integration begun in 2003, Pfizer has been reducing the number of its plants to bring capacity in line with product demand, to eliminate duplication, and to improve manufacturing efficiency. By the end of 2009, the number of global plants will have been cut by almost 50%, from 93 to 47. This reduction includes rationalization of its internal manufacturing networks and the sites included in the sale of its consumer healthcare business to J&J.

In February, Pfizer reported it would close a portion of its active pharmaceutical ingredient (API) plant at Ringaskiddy, Ireland, and would pursue the sales of its API facility in Loughbeg, Ireland, a portion of the API manufacturing facility in Little Island, Ireland, and a facility for sterile liquids in Nerviano, Italy, subject to consultation with works councils and local labor laws.

In January, Pfizer reported plans to close its manufacturing sites for solid-dosage drug production and packaging in Brooklyn, New York, and for animal-health sterile products in Omaha, Nebraska. It also plans to sell its combined API and drug-product operations in Feucht, Germany, subject to consultation with works councils and local labor laws. Pfizer also is phasing out a manufacturing facility in Groton, Connecticut. The plant makes APIs for human- and animal-health products, and the manufacture of those products will be transferred to other plants.

In 2006, Pfizer sold four facilities: a sterile production and API facility in Cruce Dávila, Puerto Rico, to Abraxis Biosciences, Inc. (Los Angeles, CA); an API facility in Augusta, Georgia, to Xethanol Corp. (New York); an API and finished-drug manufacturing plant in Uppsala, Sweden to Kemwell Pvt. Ltd. (Bangalore, India); and its API, finished dosage, and packaging facility in Morpeth, United Kingdom, to NPIL Pharma (Mumbai, India).

The Wyeth Biotech Campus Grange Castle, Ireland
Pfizer also sold its drug-product production and packaging facilities in Angers and Val de Reuil, France, to Farvea. During the next two to three years, Pfizer plans to exit an API and finished-drug manufacturing facility in Arecibo, Puerto Rico; a drug-product manufacturing and packaging facility in Arnprior, Ontario, Canada; an animal-health premix facility in Orangeville, Ontario, Canada; a liquid-filling operation in Bangkok, Thailand; animal-health premix operations in Bou Ismail, Algeria and Corby, United Kingdom; an API plant in Holland, Michigan; and finished-product plants in the following: Jakarta, Indonesia; Islamabad, Pakistan; Seoul, South Korea; Tlalpan, Mexico; Upper Merion, Pennsylvania; and Malardalen and Stockholm, Sweden. Many of these sites have already exited the network, and the remainder will exit over the ensuing two to three years, depending on works council consultation, product transfers, and regulatory approvals. Pfizer also streamlined operations at its drug-product, distribution, and fermentation operations in Sandwich, United Kingdom.

The sale of Pfizer's consumer healthcare business to J&J included finished-drug product plants in Parsippany, New Jersey; Lititz, Pennsylvania; Caringbah, Australia; Cali, Colombia; Orleans, France; Cape Town, South Africa; and Helsingborg, Sweden, as well as an associated gum-production operation in Esbjerg, Denmark.

Pfizer is planning to close its Ann Arbor, Esperion, and Kalamazoo, Michigan, research sites, but will continue to maintain a large manufacturing and animal-health presence in Kalamazoo. It is also proposing to close research sites in Nagoya, Japan, and Amboise, France, subject to consultation with works councils and local labor laws.

As it has rationalized facilities, Pfizer acquired from Sanofi-Aventis the Frankfurt, Germany, insulin-production business and facilities it previously had owned jointly with Sanofi-Aventis as part of its $1.4-billion acquisition of the rights to manufacture and sell "Exubera" inhaled insulin.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here